Additionally, an industrial scale, high-throughput proteomics production facility will be established that taps expertise at both TGen and the Biodesign Institute at ASU in robotics, protein analysis and computing.
Hartwells involvement provides the Piper Center with opportunity to draw on the Hutchinson Centers extensive capabilities in health economics and the design of clinical and public-health trials through consultative and collaborative relationships.
The Piper trustees made this investment because Dr. Hartwell has a vision to transform the prevention, diagnosis and treatment of disease, said Dr. Judy Jolley Mohraz, president and CEO of the Piper Trust. That vision draws together scientists, clinicians, engineers, statisticians, insurers and regulators to work collectively to make health care more targeted and affordable. This initiative holds the promise of making a difference in the quality of life for people here in Arizona and throughout the world.
According to John Murphy, president and CEO of the Flinn Foundation, biomarker discovery and diagnostic development could ultimately lead to earlier disease detection and more precise disease management. To leverage Arizonas institutional assets, the Flinn Foundations grant commitment to TGen will link Arizonas research universities, health care providers, research institutes and industry partners throughout the state to support the collection and storage of biospecimens and drive Arizona-centric demonstration projects, Murphy said.
Approximately 50 percent of th
|Contact: Galen Perry|
The Translational Genomics Research Institute